Diacylglycerol O Acyltransferase 1 (Diglyceride Acyltransferase 1 or ACAT Related Gene Product 1 or Acyl CoA Retinol O Fatty Acyltransferase or DGAT1 or EC 2.3.1.76 or EC 2.3.1.20) - Pipeline Review, H2 2017

  • ID: 4410090
  • Report
  • 27 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • GlaxoSmithKline Plc
  • Merck & Co Inc
  • Viking Therapeutics Inc
  • MORE
Diacylglycerol O Acyltransferase 1 (Diglyceride Acyltransferase 1 or ACAT Related Gene Product 1 or Acyl CoA Retinol O Fatty Acyltransferase or DGAT1 or EC 2.3.1.76 or EC 2.3.1.20) - Pipeline Review, H2 2017

Summary

According to the recently published report 'Diacylglycerol O Acyltransferase 1 - Pipeline Review, H2 2017'; Diacylglycerol O Acyltransferase 1 (Diglyceride Acyltransferase 1 or ACAT Related Gene Product 1 or Acyl CoA Retinol O Fatty Acyltransferase or DGAT1 or EC 2.3.1.76 or EC 2.3.1.20) pipeline Target constitutes close to 5 molecules. Out of which approximately 3 molecules are developed by companies and remaining by the universities/institutes.

Diacylglycerol O Acyltransferase 1 (Diglyceride Acyltransferase 1 or ACAT Related Gene Product 1 or Acyl CoA Retinol O Fatty Acyltransferase or DGAT1 or EC 2.3.1.76 or EC 2.3.1.20) - Diglyceride acyltransferase 1 (DGAT-1) is an enzyme that catalyzes the formation of triglycerides from diacylglycerol and Acyl-CoA. It plays a role in esterifying exogenous fatty acids to glycerol. It functions as the major acyl-CoA retinol acyltransferase (ARAT) in the skin, where it acts to maintain retinoid homeostasis and prevent retinoid toxicity leading to skin and hair disorders.

The report 'Diacylglycerol O Acyltransferase 1 - Pipeline Review, H2 2017' outlays comprehensive information on the Diacylglycerol O Acyltransferase 1 (Diglyceride Acyltransferase 1 or ACAT Related Gene Product 1 or Acyl CoA Retinol O Fatty Acyltransferase or DGAT1 or EC 2.3.1.76 or EC 2.3.1.20) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Diacylglycerol O Acyltransferase 1 (Diglyceride Acyltransferase 1 or ACAT Related Gene Product 1 or Acyl CoA Retinol O Fatty Acyltransferase or DGAT1 or EC 2.3.1.76 or EC 2.3.1.20) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase I and Preclinical stages are 1 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Metabolic Disorders, Gastrointestinal, Immunology and Undisclosed which include indications Obesity, Dyslipidemia, Hyperlipidemia, Inflammation, Non-Alcoholic Steatohepatitis (NASH), Type 2 Diabetes and Unspecified.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The report provides a snapshot of the global therapeutic landscape for Diacylglycerol O Acyltransferase 1 (Diglyceride Acyltransferase 1 or ACAT Related Gene Product 1 or Acyl CoA Retinol O Fatty Acyltransferase or DGAT1 or EC 2.3.1.76 or EC 2.3.1.20)
  • The report reviews Diacylglycerol O Acyltransferase 1 (Diglyceride Acyltransferase 1 or ACAT Related Gene Product 1 or Acyl CoA Retinol O Fatty Acyltransferase or DGAT1 or EC 2.3.1.76 or EC 2.3.1.20) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Diacylglycerol O Acyltransferase 1 (Diglyceride Acyltransferase 1 or ACAT Related Gene Product 1 or Acyl CoA Retinol O Fatty Acyltransferase or DGAT1 or EC 2.3.1.76 or EC 2.3.1.20) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Diacylglycerol O Acyltransferase 1 (Diglyceride Acyltransferase 1 or ACAT Related Gene Product 1 or Acyl CoA Retinol O Fatty Acyltransferase or DGAT1 or EC 2.3.1.76 or EC 2.3.1.20) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Diacylglycerol O Acyltransferase 1 (Diglyceride Acyltransferase 1 or ACAT Related Gene Product 1 or Acyl CoA Retinol O Fatty Acyltransferase or DGAT1 or EC 2.3.1.76 or EC 2.3.1.20) targeted therapeutics
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Diacylglycerol O Acyltransferase 1 (Diglyceride Acyltransferase 1 or ACAT Related Gene Product 1 or Acyl CoA Retinol O Fatty Acyltransferase or DGAT1 or EC 2.3.1.76 or EC 2.3.1.20)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Diacylglycerol O Acyltransferase 1 (Diglyceride Acyltransferase 1 or ACAT Related Gene Product 1 or Acyl CoA Retinol O Fatty Acyltransferase or DGAT1 or EC 2.3.1.76 or EC 2.3.1.20) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • GlaxoSmithKline Plc
  • Merck & Co Inc
  • Viking Therapeutics Inc
  • MORE
Introduction

REPORT COVERAGE

Diacylglycerol O Acyltransferase 1 (Diglyceride Acyltransferase 1 or ACAT Related Gene Product 1 or Acyl CoA Retinol O Fatty Acyltransferase or DGAT1 or EC 2.3.1.76 or EC 2.3.1.20) - Overview

Diacylglycerol O Acyltransferase 1 (Diglyceride Acyltransferase 1 or ACAT Related Gene Product 1 or Acyl CoA Retinol O Fatty Acyltransferase or DGAT1 or EC 2.3.1.76 or EC 2.3.1.20) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Diacylglycerol O Acyltransferase 1 (Diglyceride Acyltransferase 1 or ACAT Related Gene Product 1 or Acyl CoA Retinol O Fatty Acyltransferase or DGAT1 or EC 2.3.1.76 or EC 2.3.1.20) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Diacylglycerol O Acyltransferase 1 (Diglyceride Acyltransferase 1 or ACAT Related Gene Product 1 or Acyl CoA Retinol O Fatty Acyltransferase or DGAT1 or EC 2.3.1.76 or EC 2.3.1.20) - Companies Involved in Therapeutics Development

GlaxoSmithKline Plc

Merck & Co Inc

Viking Therapeutics Inc

Diacylglycerol O Acyltransferase 1 (Diglyceride Acyltransferase 1 or ACAT Related Gene Product 1 or Acyl CoA Retinol O Fatty Acyltransferase or DGAT1 or EC 2.3.1.76 or EC 2.3.1.20) - Drug Profiles

GSK-3008356 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KR-69530 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit DGAT1 for Hyperlipidemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit DGAT-1 for Inflammation and Metabolic Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit DGAT1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Diacylglycerol O Acyltransferase 1 (Diglyceride Acyltransferase 1 or ACAT Related Gene Product 1 or Acyl CoA Retinol O Fatty Acyltransferase or DGAT1 or EC 2.3.1.76 or EC 2.3.1.20) - Dormant Products

Diacylglycerol O Acyltransferase 1 (Diglyceride Acyltransferase 1 or ACAT Related Gene Product 1 or Acyl CoA Retinol O Fatty Acyltransferase or DGAT1 or EC 2.3.1.76 or EC 2.3.1.20) - Discontinued Products

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development by Stage of Development, H2 2017

Number of Products under Development by Therapy Areas, H2 2017

Number of Products under Development by Indication, H2 2017

Number of Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017

Number of Products under Investigation by Universities/Institutes, H2 2017

Products under Investigation by Universities/Institutes, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Pipeline by GlaxoSmithKline Plc, H2 2017

Pipeline by Merck & Co Inc, H2 2017

Pipeline by Viking Therapeutics Inc, H2 2017

Dormant Products, H2 2017

Dormant Products, H2 2017 (Contd..1), H2 2017

Discontinued Products, H2 2017

List of Figures

Number of Products under Development by Stage of Development, H2 2017

Number of Products under Development by Therapy Areas, H2 2017

Number of Products under Development by Indications, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Stage and Route of Administrations, H2 2017
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • GlaxoSmithKline Plc
  • Merck & Co Inc
  • Viking Therapeutics Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll